- Home
- KROS vs NKX Comparison
KROS vs NKX Comparison
Compare KROS & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- NKX
- Stock Information
- Founded
- KROS 2015
- NKX 2002
- Country
- KROS United States
- NKX United States
- Employees
- KROS N/A
- NKX N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- NKX Finance/Investors Services
- Sector
- KROS Health Care
- NKX Finance
- Exchange
- KROS Nasdaq
- NKX Nasdaq
- Market Cap
- KROS 589.8M
- NKX 599.7M
- IPO Year
- KROS 2020
- NKX N/A
- Fundamental
- Price
- KROS $11.98
- NKX $12.62
- Analyst Decision
- KROS Buy
- NKX
- Analyst Count
- KROS 11
- NKX 0
- Target Price
- KROS $45.33
- NKX N/A
- AVG Volume (30 Days)
- KROS 2.0M
- NKX 109.3K
- Earning Date
- KROS 02-26-2025
- NKX 01-01-0001
- Dividend Yield
- KROS N/A
- NKX 4.37%
- EPS Growth
- KROS N/A
- NKX N/A
- EPS
- KROS N/A
- NKX N/A
- Revenue
- KROS $651,000.00
- NKX N/A
- Revenue This Year
- KROS $303.27
- NKX N/A
- Revenue Next Year
- KROS N/A
- NKX N/A
- P/E Ratio
- KROS N/A
- NKX N/A
- Revenue Growth
- KROS 8037.50
- NKX N/A
- 52 Week Low
- KROS $9.78
- NKX $9.78
- 52 Week High
- KROS $73.00
- NKX $12.00
- Technical
- Relative Strength Index (RSI)
- KROS 25.14
- NKX 46.89
- Support Level
- KROS $10.95
- NKX $12.42
- Resistance Level
- KROS $11.63
- NKX $12.92
- Average True Range (ATR)
- KROS 0.88
- NKX 0.19
- MACD
- KROS 1.25
- NKX 0.01
- Stochastic Oscillator
- KROS 32.42
- NKX 42.00
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.